Firelink™ DAC platform
The Firelink™ DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue—a key limitation of many current treatment approaches.
Johnson & Johnson
Johnson & Johnson revenue93
Quarterly and annual revenue from company filings.
Business drivers
Business lines and operating measures.
Med Tech revenue
Reported quarterly Med Tech revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Sep 27, 2026From Jun 29, 2026 | 8,642,000,000 | Filed Oct 21, 2026 |
| Jun 28, 2026From Mar 30, 2026 | 8,926,000,000 | Filed Jul 23, 2026 |
| Sep 28, 2025From Jun 30, 2025 | 8,430,000,000 | Filed Oct 21, 2026 |
| Jun 29, 2025From Mar 31, 2025 | 8,541,000,000 | Filed Jul 23, 2026 |
Innovative Medicine revenue
Reported quarterly Innovative Medicine revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Sep 27, 2026From Jun 29, 2026 | 16,757,000,000 | Filed Oct 21, 2026 |
| Jun 28, 2026From Mar 30, 2026 | 16,384,000,000 | Filed Jul 23, 2026 |
| Sep 28, 2025From Jun 30, 2025 | 15,563,000,000 | Filed Oct 21, 2026 |
| Jun 29, 2025From Mar 31, 2025 | 15,202,000,000 | Filed Jul 23, 2026 |
Independent series; they may overlap and do not form an additive breakdown.
Products & projects
Sail's in vivo CAR-T platform
Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time.
Revenue history
USD millions · Fiscal periodsQuarterly data
| Fiscal quarter | Ended | Total revenueUSD millions |
|---|---|---|
| FY 2026 Q3 | Sep 27, 2026 | 25,399, +0.4% versus FY 2026 Q2 |
| FY 2026 Q2 | Jun 28, 2026 | 25,310, +5.2% versus FY 2026 Q1 |
| FY 2026 Q1 | Mar 29, 2026 | 24,062, −2.0% versus FY 2025 Q4 |
| FY 2025 Q4 | Dec 28, 2025 | 24,564, +2.4% versus FY 2025 Q3 |
| FY 2025 Q3 | Sep 28, 2025 | 23,993, +1.1% versus FY 2025 Q2 |
| FY 2025 Q2 | Jun 29, 2025 | 23,743, +8.5% versus FY 2025 Q1 |
| FY 2025 Q1 | Mar 30, 2025 | 21,893, −2.8% versus FY 2024 Q4 |
| FY 2024 Q4 | Dec 29, 2024 | 22,520, +0.2% versus FY 2024 Q3 |
| FY 2024 Q3 | Sep 29, 2024 | 22,471, +0.1% versus FY 2024 Q2 |
| FY 2024 Q2 | Jun 30, 2024 | 22,447, +5.0% versus FY 2024 Q1 |
| FY 2024 Q1 | Mar 31, 2024 | 21,383, −0.1% versus FY 2023 Q4 |
| FY 2023 Q4 | Dec 31, 2023 | 21,395, +0.2% versus FY 2023 Q3 |
| FY 2023 Q3 | Oct 1, 2023 | 21,351, −16.4% versus FY 2023 Q2 |
| FY 2023 Q2 | Jul 2, 2023 | 25,530, +3.2% versus FY 2023 Q1 |
| FY 2023 Q1 | Apr 2, 2023 | 24,746, +24.1% versus FY 2022 Q4 |
| FY 2022 Q4 | Jan 1, 2023 | 19,939, −16.2% versus FY 2022 Q3 |
| FY 2022 Q3 | Oct 2, 2022 | 23,791, −1.0% versus FY 2022 Q2 |
| FY 2022 Q2 | Jul 3, 2022 | 24,020, +2.5% versus FY 2022 Q1 |
| FY 2022 Q1 | Apr 3, 2022 | 23,426, −5.6% versus FY 2021 Q4 |
| FY 2021 Q4 | Jan 2, 2022 | 24,804, +6.3% versus FY 2021 Q3 |
| FY 2021 Q3 | Oct 3, 2021 | 23,338, +0.1% versus FY 2021 Q2 |
| FY 2021 Q2 | Jul 4, 2021 | 23,312, +4.4% versus FY 2021 Q1 |
| FY 2021 Q1 | Apr 4, 2021 | 22,321, −0.7% versus FY 2020 Q4 |
| FY 2020 Q4 | Jan 3, 2021 | 22,475, +6.6% versus FY 2020 Q3 |
| FY 2020 Q3 | Sep 27, 2020 | 21,082, +15.0% versus FY 2020 Q2 |
| FY 2020 Q2 | Jun 28, 2020 | 18,336, −11.4% versus FY 2020 Q1 |
| FY 2020 Q1 | Mar 29, 2020 | 20,691, −0.3% versus FY 2019 Q4 |
| FY 2019 Q4 | Dec 29, 2019 | 20,747, +0.1% versus FY 2019 Q3 |
| FY 2019 Q3 | Sep 29, 2019 | 20,729, +0.8% versus FY 2019 Q2 |
| FY 2019 Q2 | Jun 30, 2019 | 20,562, +2.7% versus FY 2019 Q1 |
| FY 2019 Q1 | Mar 31, 2019 | 20,021, −1.8% versus FY 2018 Q4 |
| FY 2018 Q4 | Dec 30, 2018 | 20,394, +0.2% versus FY 2018 Q3 |
| FY 2018 Q3 | Sep 30, 2018 | 20,348, −2.3% versus FY 2018 Q2 |
| FY 2018 Q2 | Jul 1, 2018 | 20,830, +4.1% versus FY 2018 Q1 |
| FY 2018 Q1 | Apr 1, 2018 | 20,009, −0.9% versus FY 2017 Q4 |
| FY 2017 Q4 | Dec 31, 2017 | 20,195, +2.8% versus FY 2017 Q3 |
| FY 2017 Q3 | Oct 1, 2017 | 19,650, +4.3% versus FY 2017 Q2 |
| FY 2017 Q2 | Jul 2, 2017 | 18,839, +6.0% versus FY 2017 Q1 |
| FY 2017 Q1 | Apr 2, 2017 | 17,766, −1.9% versus FY 2016 Q4 |
| FY 2016 Q4 | Jan 1, 2017 | 18,106, +1.6% versus FY 2016 Q3 |
| FY 2016 Q3 | Oct 2, 2016 | 17,820, −3.6% versus FY 2016 Q2 |
| FY 2016 Q2 | Jul 3, 2016 | 18,482, +5.7% versus FY 2016 Q1 |
| FY 2016 Q1 | Apr 3, 2016 | 17,482, −1.8% versus FY 2015 Q4 |
| FY 2015 Q4 | Jan 3, 2016 | 17,811, +4.1% versus FY 2015 Q3 |
| FY 2015 Q3 | Sep 27, 2015 | 17,102, −3.9% versus FY 2015 Q2 |
| FY 2015 Q2 | Jun 28, 2015 | 17,787, +2.4% versus FY 2015 Q1 |
| FY 2015 Q1 | Mar 29, 2015 | 17,374, −4.8% versus FY 2014 Q4 |
| FY 2014 Q4 | Dec 28, 2014 | 18,254, −1.2% versus FY 2014 Q3 |
| FY 2014 Q3 | Sep 28, 2014 | 18,467, −5.3% versus FY 2014 Q2 |
| FY 2014 Q2 | Jun 29, 2014 | 19,495, +7.6% versus FY 2014 Q1 |
| FY 2014 Q1 | Mar 30, 2014 | 18,115, −1.3% versus FY 2013 Q4 |
| FY 2013 Q4 | Dec 29, 2013 | 18,355, +4.4% versus FY 2013 Q3 |
| FY 2013 Q3 | Sep 29, 2013 | 17,575, −1.7% versus FY 2013 Q2 |
| FY 2013 Q2 | Jun 30, 2013 | 17,877, +2.1% versus FY 2013 Q1 |
| FY 2013 Q1 | Mar 31, 2013 | 17,505, −0.3% versus FY 2012 Q4 |
| FY 2012 Q4 | Dec 30, 2012 | 17,558, +3.0% versus FY 2012 Q3 |
| FY 2012 Q3 | Sep 30, 2012 | 17,052, +3.5% versus FY 2012 Q2 |
| FY 2012 Q2 | Jul 1, 2012 | 16,475, +2.1% versus FY 2012 Q1 |
| FY 2012 Q1 | Apr 1, 2012 | 16,139, −0.7% versus FY 2011 Q4 |
| FY 2011 Q4 | Jan 1, 2012 | 16,255, +1.6% versus FY 2011 Q3 |
| FY 2011 Q3 | Oct 2, 2011 | 16,005, −3.6% versus FY 2011 Q2 |
| FY 2011 Q2 | Jul 3, 2011 | 16,597, +2.6% versus FY 2011 Q1 |
| FY 2011 Q1 | Apr 3, 2011 | 16,173, +3.4% versus FY 2010 Q4 |
| FY 2010 Q4 | Jan 2, 2011 | 15,644, +4.4% versus FY 2010 Q3 |
| FY 2010 Q3 | Oct 3, 2010 | 14,982, −2.3% versus FY 2010 Q2 |
| FY 2010 Q2 | Jul 4, 2010 | 15,330, −1.9% versus FY 2010 Q1 |
| FY 2010 Q1 | Apr 4, 2010 | 15,631, −5.6% versus FY 2009 Q4 |
| FY 2009 Q4 | Jan 3, 2010 | 16,551, +9.7% versus FY 2009 Q3 |
| FY 2009 Q3 | Sep 27, 2009 | 15,081, −1.0% versus FY 2009 Q2 |
| FY 2009 Q2 | Jun 28, 2009 | 15,239, Change unavailable versus FY 2009 Q1 |
Sources and definitions
Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.
Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.
Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.
- Total revenue
- Reported consolidated revenue as tagged in the SEC filing, including all company businesses.
- SEC company facts · CIK 200406 · Retrieved Oct 22, 2026
- SEC financial report · Retrieved Oct 22, 2026
Annual and quarterly differences
- FY 2022 · Total revenue: annual 94,943, quarter sum 91,176 USD millions.
- FY 2023 · Total revenue: annual 85,159, quarter sum 93,022 USD millions.